Global Companion Radiodiagnostics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

What is the Companion Radiodiagnostics Market Size and Growth Rate?

• As per Data Bridge Market Research analysis, the companion radiodiagnostics market was valued at USD 2.48 billion in 2025 and is projected to reach USD 5.67 billion by 2033, growing at a CAGR of 10.90% from 2026 to 2033.
• The market is witnessing consistent expansion due to the increasing use of molecular imaging techniques, advancements in positron emission tomography (PET), magnetic resonance imaging (MRI), and other radiodiagnostic platforms, along with rising investments in oncology-focused companion diagnostic solutions.
• The growing prevalence of cancer and other chronic diseases, combined with the increasing need for targeted therapies and patient-specific treatment strategies, is encouraging pharmaceutical companies, diagnostic laboratories, and healthcare providers to adopt companion radiodiagnostic technologies. These imaging-based diagnostic approaches enable improved patient stratification, therapy monitoring, and evaluation of treatment response, supporting the advancement of precision medicine and personalized healthcare.

Market Size & Forecast

• Global Market Value (2025): USD 2.48 Billion
• Expected Market Value (2033): USD 5.67 Billion
• Forecast CAGR (2026–2033): 10.90%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia Pacific

What are the Major Takeaways of the Companion Radiodiagnostics Market?

• North America dominated the companion diagnostics market with the largest revenue share of 39.9% in 2025, supported by advanced healthcare infrastructure, increasing adoption of precision medicine, rising prevalence of cancer and chronic diseases, and strong regulatory support for targeted therapies
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 12.5% from 2026 to 2033, fueled by increasing healthcare investments, rising adoption of advanced diagnostic technologies, growing cancer burden, and expanding precision medicine initiatives across China, Japan, India, and South Korea.
• The assays, kits & reagents segment led the market with a 55.0% share in 2025, driven by increasing demand for biomarker detection solutions, molecular diagnostic testing, and patient stratification tools used in precision medicine.
• Software & services are the fastest-growing product & services type, projected to register a CAGR of 12.4%, reflecting the surge in adoption of digital pathology, artificial intelligence (AI)-based imaging analytics, and data interpretation platforms.
• The polymerase chain reaction (PCR) segment dominated the technology category with a 30% revenue share in 2025, led by its widespread adoption in molecular diagnostics, high sensitivity, and ability to detect specific genetic biomarkers.
• Positron emission tomography (PET) accounted for 40% of the market share in 2025, preferred by increasing adoption of molecular imaging techniques for oncology diagnosis, treatment selection, and therapy monitoring.
• The neurological disorders segment is the fastest-growing indication category, with a CAGR of 13.5%, driven by increasing adoption of advanced imaging biomarkers for conditions such as Alzheimer’s disease and Parkinson’s disease.

Report Scope and Companion Radiodiagnostics Market Segmentation         

What is the Key Trend in the Companion Radiodiagnostics Market?

• Integration of artificial intelligence (AI) and advanced imaging analytics is emerging as a major trend in companion radiodiagnostics, enabling improved image interpretation, biomarker identification, and personalized treatment planning.
• For instance, in March 2024, GE HealthCare and Mass General Brigham expanded their artificial intelligence collaboration to develop medical imaging foundation models, focusing on AI-driven solutions for diagnostic workflows and improving the use of imaging data in clinical decision-making.
• AI-powered radiodiagnostic platforms are increasingly being adopted to analyze complex imaging data, improve diagnostic accuracy, and support precision oncology workflows through faster and more reliable clinical decision-making.
• Advanced molecular imaging techniques, including PET and MRI-based approaches, are being increasingly integrated with companion diagnostic strategies to identify suitable patients and monitor therapeutic response.
• Pharmaceutical companies and imaging technology providers are expanding collaborations to develop imaging biomarkers that support targeted therapies and improve clinical trial efficiency.
• For instance, in November 2024, GE HealthCare and RadNet announced a collaboration to accelerate adoption of AI-powered imaging solutions, combining AI-based clinical workflows with imaging systems to improve image interpretation, operational efficiency, and radiology care delivery.
• As precision medicine adoption continues to expand globally, the integration of AI, molecular imaging, and radiodiagnostic biomarkers is expected to accelerate, strengthening the role of companion radiodiagnostics in targeted therapy selection and treatment monitoring.

What are the Key Drivers of the Companion Radiodiagnostics Market?

• The rising prevalence of cancer and increasing adoption of targeted therapies have significantly increased demand for companion radiodiagnostics capable of identifying biomarkers and guiding personalized treatment decisions.
• For instance, in March 2025, the U.S. Food and Drug Administration expanded the indication of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for PSMA-positive metastatic castration-resistant prostate cancer, requiring patient selection using approved PSMA PET imaging products, further strengthening the role of molecular imaging in precision oncology.
• The growing use of precision oncology approaches is encouraging pharmaceutical companies and healthcare providers to integrate imaging-based diagnostics with therapeutic development programs to improve patient outcomes.
• Healthcare organizations are increasingly adopting companion radiodiagnostic technologies to enhance patient stratification, monitor treatment response, and reduce ineffective therapy selection in clinical practice.
• The increasing regulatory approvals for imaging biomarkers and radiopharmaceutical diagnostic agents continue to strengthen market growth by supporting broader clinical adoption across oncology and other therapeutic areas.
• For instance, in December 2022, the U.S. Food and Drug Administration approved Locametz (gallium Ga 68 gozetotide), a PSMA-targeted PET imaging agent, to identify PSMA-positive lesions in patients with prostate cancer, supporting biomarker-based patient selection and personalized treatment planning.
• With rising demand for personalized healthcare solutions and biomarker-driven therapies, companion radiodiagnostics are expected to become increasingly important for improving diagnostic precision and optimizing treatment pathways.

Which Factors are Challenging the Growth of the Next Generation Tobacco Products Market?

• High development and implementation costs associated with advanced imaging systems, molecular imaging agents, and companion diagnostic validation processes create significant barriers to market adoption.
• For instance, in January 2024, the European Society of Radiology (ESR), along with other leading radiology organizations, highlighted practical challenges associated with implementing advanced AI-based imaging technologies, including purchasing decisions, infrastructure requirements, monitoring, and integration into clinical workflows
• The requirement for specialized infrastructure, regulatory approvals, and skilled professionals limits the adoption of radiodiagnostic technologies, particularly in emerging economies and smaller healthcare facilities.
• Complex reimbursement policies and variations in healthcare coverage for advanced diagnostic imaging procedures continue to restrict widespread utilization of companion radiodiagnostic solutions.
• The high capital investment, operational expenses, and regulatory complexities associated with companion radiodiagnostic development continue to slow adoption despite increasing demand for precision medicine and targeted treatment approaches.
• For instance, in October 2024, the American College of Radiology (ACR) highlighted declining reimbursement pressures, workforce shortages, and increasing operational challenges as key issues affecting radiology practice and healthcare delivery.
• These cost and accessibility challenges remain key limitations, particularly for healthcare providers operating in resource-constrained regions where advanced molecular imaging infrastructure is still developing.

How is the Companion Radiodiagnostics Market Segmented?

The companion radiodiagnostics market is segmented on the basis of product & services, technology, radiodiagnostic modality, indication, and end user.

• By Product & Services

On the basis of product & services, the companion radiodiagnostics market is segmented into assays, kits & reagents, instruments & systems, and software & services. The assays, kits & reagents segment dominated the market with an estimated share of 55.0% in 2025, owing to increasing demand for biomarker detection solutions, molecular diagnostic testing, and patient stratification tools used in precision medicine. These products are widely utilized for identifying specific biomarkers associated with targeted therapies, particularly in oncology applications. Growing adoption of companion diagnostic assays alongside pharmaceutical therapies is strengthening segment growth. Increasing regulatory approvals for biomarker-based diagnostic tests are further supporting demand. Pharmaceutical and biotechnology companies are increasingly integrating assay-based companion diagnostics into clinical trials and drug development programs. The availability of standardized testing kits and reagents also supports their widespread adoption across diagnostic laboratories and healthcare institutions.

The software & services segment is projected to be the fastest-growing product category, expanding at a CAGR of 12.4% from 2026 to 2033, driven by increasing adoption of digital pathology, artificial intelligence (AI)-based imaging analytics, and data interpretation platforms. Software solutions are enabling advanced analysis of complex radiodiagnostic data and improving clinical decision-making. Growing integration of AI algorithms with imaging platforms is enhancing diagnostic accuracy and workflow efficiency. Cloud-based diagnostic solutions are gaining traction due to their ability to support remote analysis and data sharing. Increasing demand for personalized treatment planning is encouraging healthcare providers to adopt advanced analytical services. Rising collaborations between technology companies and healthcare organizations are further accelerating innovation in this segment.

• By Technology

On the basis of technology, the companion radiodiagnostics market is segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry (IHC), in-situ hybridization (ISH), magnetic resonance imaging (MRI), and other technologies. The polymerase chain reaction (PCR) segment dominated the market with an estimated share of 30% in 2025, supported by its widespread adoption in molecular diagnostics, high sensitivity, and ability to detect specific genetic biomarkers. PCR-based technologies are extensively used for identifying mutations and genetic alterations associated with targeted therapies. Their relatively lower cost and established clinical applications have contributed to strong adoption across diagnostic laboratories. Increasing demand for rapid and accurate biomarker testing is supporting segment expansion. PCR technologies are widely utilized in oncology companion diagnostics for treatment selection and monitoring. Continuous improvements in multiplex PCR and real-time PCR technologies are further enhancing their clinical utility.

The next-generation sequencing (NGS) segment is expected to witness the fastest growth at a CAGR of 15.7% during the forecast period, driven by increasing demand for comprehensive genomic profiling and personalized medicine applications. NGS enables simultaneous analysis of multiple genetic alterations, supporting more accurate patient selection for targeted therapies. Growing adoption of precision oncology is significantly increasing demand for genomic-based companion diagnostic solutions. Pharmaceutical companies are increasingly incorporating NGS-based testing into clinical trials for targeted drug development. Declining sequencing costs and technological advancements are improving accessibility of NGS platforms. Expansion of genomic databases and bioinformatics capabilities is further accelerating adoption globally.

• By Radiodiagnostic Modality

On the basis of radiodiagnostic modality, the market is segmented into magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), single photon emission computed tomography (SPECT), and other imaging modalities. The positron emission tomography (PET) segment dominated the market with an estimated share of 40% in 2025, driven by increasing adoption of molecular imaging techniques for oncology diagnosis, treatment selection, and therapy monitoring. PET imaging enables visualization of biological processes at the molecular level, making it highly valuable for precision medicine applications. Increasing use of PET-based biomarkers, including PSMA-targeted imaging agents, is strengthening market demand. Growing prevalence of cancer and rising adoption of targeted radiopharmaceutical therapies are supporting segment growth. PET imaging plays a critical role in identifying suitable patients for personalized treatment approaches. Continuous advancements in radiotracer development are further expanding clinical applications.

The magnetic resonance imaging (MRI) segment is expected to register the fastest growth at a CAGR of 10.2% from 2026 to 2033, supported by increasing adoption of advanced imaging technologies for non-invasive disease characterization and treatment monitoring. MRI provides high-resolution anatomical and functional information without ionizing radiation exposure. Growing use of AI-enabled MRI analysis is improving diagnostic accuracy and workflow efficiency. Increasing applications in oncology, neurological disorders, and cardiovascular diseases are expanding MRI utilization. Development of quantitative imaging biomarkers is creating new opportunities for companion radiodiagnostic applications. Rising healthcare investments in advanced imaging infrastructure are further supporting segment expansion.

• By Indication

On the basis of indication, the companion radiodiagnostics market is segmented into oncology, infectious diseases, cardiovascular diseases, neurological disorders, and other indications. The oncology segment dominated the market with an estimated share of 55.0% in 2025, driven by increasing demand for personalized cancer treatment approaches and biomarker-based patient selection. Companion radiodiagnostics are extensively used in oncology for identifying suitable candidates for targeted therapies and monitoring treatment response. Rising global cancer prevalence is increasing demand for advanced diagnostic imaging solutions. Molecular imaging techniques such as PET are increasingly being adopted for tumor characterization and therapy planning. Growing approvals of targeted cancer therapies are encouraging integration of companion diagnostics into clinical workflows. Pharmaceutical companies are also investing heavily in oncology-focused companion diagnostic development.

The neurological disorders segment is projected to be the fastest-growing indication segment, expanding at a CAGR of 13.5%, driven by increasing adoption of advanced imaging biomarkers for conditions such as Alzheimer’s disease and Parkinson’s disease. Molecular imaging techniques are enabling earlier disease detection and improved monitoring of neurological progression. Growing research into neurodegenerative disease biomarkers is supporting segment expansion. Increasing demand for personalized neurological treatment approaches is encouraging adoption of advanced radiodiagnostic solutions. AI-based imaging analysis is further improving interpretation of neurological imaging data. Rising healthcare burden associated with aging populations is expected to accelerate demand for neurological companion diagnostics.

• By End User

On the basis of end user, the companion radiodiagnostics market is segmented into hospitals & physician laboratories, diagnostic laboratories, reference laboratories, academic & research centers, contract research organizations (CROs), pharmaceutical & biotechnology companies, and other end users. The pharmaceutical & biotechnology companies segment dominated the market with an estimated share of 35% in 2025, supported by increasing integration of companion diagnostics into drug discovery, clinical trials, and targeted therapy development. These companies utilize companion radiodiagnostics to identify suitable patient populations and improve therapeutic outcomes. Growing partnerships between pharmaceutical firms and diagnostic developers are accelerating market expansion. Companion diagnostics help reduce clinical trial costs by enabling efficient patient selection. Increasing focus on precision medicine pipelines is further strengthening demand from this segment. Regulatory emphasis on co-development of therapies and diagnostics is also supporting adoption.

The academic & research centers segment is expected to be the fastest-growing end-user category, expanding at a CAGR of 13.5%, driven by increasing research activities in molecular imaging, biomarker discovery, and personalized medicine. Research institutions are increasingly adopting advanced imaging technologies for developing novel diagnostic approaches. Growing government funding for precision medicine initiatives is supporting expansion of research-based applications. Academic collaborations with pharmaceutical and biotechnology companies are accelerating innovation. Increasing clinical research activities involving imaging biomarkers are creating new opportunities. Expansion of translational research programs is further driving adoption of companion radiodiagnostic technologies.

Which Region Holds the Largest Share of the Companion Radiodiagnostics Market?

• North America dominated the companion diagnostics market with the largest revenue share of 39.9% in 2025, supported by advanced healthcare infrastructure, increasing adoption of precision medicine, rising prevalence of cancer and chronic diseases, and strong regulatory support for targeted therapies
• The region also benefits from favorable regulatory frameworks, increasing approvals of molecular imaging and companion diagnostic solutions, and growing adoption of AI-enabled imaging technologies across oncology and personalized healthcare applications. Rising investments in targeted therapies, radiopharmaceutical development, and biomarker-based diagnostics continue to strengthen North America’s leadership position in the global market.

U.S. Companion Radiodiagnostics Market Insight

The U.S. companion radiodiagnostics market is witnessing strong growth due to increasing adoption of precision medicine, rising prevalence of cancer, and growing utilization of molecular imaging technologies for targeted treatment selection. The country’s advanced healthcare infrastructure, strong pharmaceutical research ecosystem, and presence of leading diagnostic and biotechnology companies are driving demand for PET-based imaging biomarkers and AI-enabled diagnostic solutions. In addition, increasing FDA approvals of radiopharmaceutical imaging agents and companion diagnostic tools are accelerating adoption across oncology and personalized healthcare applications. In March 2022, the U.S. Food and Drug Administration approved Locametz (gallium Ga 68 gozetotide), a PSMA-targeted PET imaging agent, for PET imaging of PSMA-positive lesions in men with prostate cancer and for selecting patients eligible for PSMA-directed therapy, supporting the growing adoption of molecular imaging-based precision oncology approaches.

Asia-Pacific Companion Radiodiagnostics Market Insight

The Asia-Pacific companion radiodiagnostics market is expected to witness rapid growth, driven by rising cancer prevalence, expanding healthcare infrastructure, increasing adoption of precision medicine, and growing investments in molecular imaging technologies across countries such as China, Japan, and India. Growing government initiatives for advanced diagnostics, increasing availability of PET imaging facilities, and rising pharmaceutical research activities are supporting regional market expansion. In addition, increasing collaborations between biotechnology companies, research institutions, and healthcare providers are accelerating adoption of companion radiodiagnostic solutions across oncology and other therapeutic areas. In June 2024, China’s National Medical Products Administration (NMPA) approved AstraZeneca’s Tagrisso (osimertinib) in combination with chemotherapy as a first-line treatment for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), supporting the expansion of biomarker-driven precision oncology and targeted treatment approaches in China.

Japan Companion Radiodiagnostics Market Insight

The Japan companion radiodiagnostics market is witnessing consistent growth due to increasing adoption of molecular imaging technologies, advanced cancer diagnostics, and government-supported precision medicine initiatives. Pharmaceutical companies, hospitals, and research institutes are increasingly utilizing PET imaging and biomarker-based diagnostic approaches for treatment selection and disease monitoring. Moreover, Japan’s strong healthcare system, aging population, and focus on innovative cancer therapies are further contributing to market growth. Japan approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of prostate cancer, following PSMA-targeted imaging approaches for identifying eligible patients, supporting the growth of theranostics and molecular imaging applications

China Companion Radiodiagnostics Market Insight

The China companion radiodiagnostics market is growing rapidly, driven by increasing cancer burden, expanding precision medicine programs, and rising investments in advanced diagnostic imaging infrastructure. Growing adoption of PET imaging, radiopharmaceutical development, and biomarker-based treatment strategies across major hospitals is significantly boosting market demand. In addition, government initiatives supporting innovative drug development, healthcare modernization, and domestic biotechnology growth are positioning China as one of the fastest-growing markets for companion radiodiagnostics globally. China’s National Health Commission continued promoting cancer prevention and early diagnosis initiatives, encouraging wider adoption of advanced diagnostic technologies and precision healthcare approaches.

U.K. Companion Radiodiagnostics Market Insight

The U.K. companion radiodiagnostics market is experiencing steady growth, supported by increasing adoption of precision oncology, advanced imaging technologies, and research activities in molecular diagnostics. The country’s strong clinical research ecosystem, National Health Service (NHS) infrastructure, and focus on personalized healthcare are contributing to wider implementation of imaging-based diagnostic approaches. Furthermore, increasing investments in radiopharmaceutical research and AI-enabled imaging solutions are improving diagnostic capabilities and supporting market development. NHS England expanded access to genomic testing through the NHS Genomic Medicine Service, supporting personalized treatment decisions and biomarker-driven healthcare approaches.

Germany Companion Radiodiagnostics Market Insight

The Germany companion radiodiagnostics market is expanding steadily due to the country’s advanced healthcare infrastructure, strong pharmaceutical industry, and increasing adoption of molecular imaging technologies. Hospitals, research organizations, and biotechnology companies are increasingly utilizing PET-based diagnostics, imaging biomarkers, and precision medicine solutions for oncology applications. Continuous investments in radiopharmaceutical research, digital healthcare, and AI-based imaging technologies, along with Germany’s strong clinical research capabilities, are further driving market growth. Germany’s Federal Ministry of Education and Research (BMBF) continued supporting personalized medicine research initiatives aimed at improving biomarker discovery, diagnostics, and individualized treatment strategies.

Which are the Top Companies in Companion Radiodiagnostics Market?

The companion radiodiagnostics industry is primarily led by well-established companies, including:

• Telix Pharmaceuticals Limited (Australia)
• Novartis AG (Switzerland)
• Siemens Healthineers AG (Germany)
• GE HealthCare (U.S.)
• Koninklijke Philips N.V. (Netherlands)
• CANON MEDICAL SYSTEMS CORPORATION (Japan)
• Esaote S.p.A. (Italy)
• Bruker Corporation (U.S.)
• Bayer AG (Germany)
• Curium Pharma (France)
• Cardinal Health, Inc. (U.S.)
• Nordion Inc. (Canada)
• IBA Radiopharma Solutions (Belgium)
• Blue Earth Diagnostics Limited (U.K.)
• Life Molecular Imaging Ltd. (Germany)
• SOFIE Biosciences, Inc. (U.S.)
• Jubilant Radiopharma (Canada)
• NCM USA Inc. (U.S.)

What are Latest Developments in Companion Radiodiagnostics Market?

• In June 2025, Telix Pharmaceuticals announced the commercial launch of Gozellix (kit for the preparation of gallium-68 gozetotide injection) in the U.S., a next-generation PSMA-PET imaging agent designed for PET imaging of PSMA-positive lesions in men with prostate cancer. The product launch expanded availability of molecular imaging solutions for prostate cancer diagnosis and strengthened adoption of companion radiodiagnostic approaches for biomarker-based patient selection
• In March 2025, Telix Pharmaceuticals received U.S. FDA approval for Gozellix (TLX007-CDx; gallium Ga 68 gozetotide injection kit), a next-generation PSMA-PET imaging agent for prostate cancer. The product launch expanded access to molecular imaging by enabling PET visualization of PSMA-positive lesions and supporting patient selection for targeted prostate cancer therapies.
• In February 2025, the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) approved gozetotide (Illuccix) as a PSMA-targeted PET imaging agent for detecting prostate cancer lesions. The product approval enabled healthcare professionals to visualize PSMA-expressing cancer cells through PET imaging, supporting improved diagnosis, treatment planning, and biomarker-based patient management in precision oncology.
• In May 2023, Blue Earth Diagnostics received U.S. FDA approval for POSLUMA (flotufolastat F 18), a radiohybrid PSMA-targeted PET imaging agent for detecting PSMA-positive lesions in men with prostate cancer. The product launch introduced an advanced molecular imaging option that supports disease localization, treatment planning, and personalized oncology decision-making.
• In May 2021, Lantheus announced the U.S. FDA approval of Pylarify (piflufolastat F 18), a PSMA-targeted PET imaging agent developed for detecting PSMA-positive prostate cancer lesions. The product introduction expanded access to PET-based molecular imaging and supported improved identification of patients eligible for targeted prostate cancer therapies.

SKU-76593